Cymbalta (duloxetine) is a prescription medication indicated in the treatment of both MDD and GAD. Cymbalta belongs to a group of
Cymbalta is indicated for the treatment of generalized anxiety disorder (GAD). The efficacy of. Cymbalta was established in three short-term trials and one
In November 2024, the FDA approved Cymbalta for the maintenance of GAD. The FDA approved Cymbalta to treat GAD in children and adolescents in 2024. However
Cymbalta is indicated for the treatment of major depressive disorder (MDD). Cymbalta is indicated for the treatment of generalized anxiety disorder (GAD).
In February 2024, the FDA approved Cymbalta for the treatment of generalized anxiety disorder (GAD). In November 2024, the FDA approved Cymbalta for the maintenance of GAD. The FDA approved Cymbalta to treat GAD in children and adolescents in 2024.
Cymbalta or other drugs to effectively resolve Cymbalta is prescribed to treat depression, generalized anxiety disorder (GAD)
Cymbalta is indicated for the treatment of generalized anxiety disorder (GAD). The effectiveness of Cymbalta in hospitalized patients with major
The efficacy and safety of Cymbalta for the maintenance treatment of GAD were established in a double-blind, placebo-controlled trial. Patients with GAD who
Cymbalta is indicated for the treatment of generalized anxiety disorder (GAD). Cymbalta therapy does not affect their ability to engage in such activities.
Comments